Scantox enters transformational acquisition of QPS Neuropharmacology
Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract Research Organization (CRO) that specializes in neurodegenerative, rare diseases and mental disorders.
Immedica announces that Loargys® (pegzilarginase) receives positive opinion by the CHMP
Immedica today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D) in patients two years and older.
Scantox acquires Q&Q Labs – strengthening its offering within bioanalytical services
Scantox acquires Q&Q – strengthening its offering within bioanalytical services
Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner
Impilo invests in Pelago Bioscience AB and enters a partnership with the Founders to accelerate platform expansion. Pelago is a fast-growing drug discovery focused contract research organisation (“CRO”) with a service offering centered around its patented CEllular Thermal Shift Assay (CETSA®) technology. CETSA® provides unique value to customers in accelerating drug discovery projects given its ability to quantify how a drug compound binds to its intended target and perturb the biology in whole-cell physiological conditions. The Company enjoys strong market tailwinds, serves a steadily growing global customer base of leading pharmaceutical and biotechnology companies from its state-of-the-art laboratory in Stockholm, and is well-positioned to capture a significantly larger share of drug discovery projects globally.
Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider
VaccinDirekt is the leading Nordic vaccination provider in a winning channel enjoying strong underlying growth, primarily driven by increased public awareness for vaccines, the enhanced focus on preventive healthcare, and a steadily growing pipeline of new vaccines. The Company is well positioned to extend its leadership, leveraging its unparalleled quality, know-how, and customer focus, coupled with a large physical footprint in central locations, offering superior convenience and availability to its growing base of more than 1.4 million registered customers.
Immedica acquires global rights to pegzilarginase from Aeglea
Immedica announces that it has signed an agreement to acquire the global rights to pegzilarginase and related assets from Aeglea BioTherapeutics, Inc. The acquisition means that the previously entered exclusive license and supply agreement from 2021 of the rights to pegzilarginase in Europe and the Middle East will be superseded.
Impilo invests in Decon – a leading mobility player within power-assisted electrical wheelchair solutions
Impilo has acquired a majority position in Decon Wheel AB (“Decon”), a developer and producer of high-quality power assist electrical solutions for manual wheelchairs, from its founders, who will continue as minority owners.
Impilo joins the ESG Data Convergence Initiative reaffirms commitment to ESG disclosure and standardization
Impilo AB, today announced that it has joined the ESG Data Convergence Initiative, a global effort to improve ESG (Environmental, Social, and Governance) data standardization and disclosure.
Sustainability Report for 2022
During 2022, significant progress was made to implement and anchor Impilo’s Sustainability Blueprint with our portfolio companies. We always aim to accelerate positive health outcomes through our investments and welcome you to read more about our progress in Impilo’s Sustainability Report 2022
Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets
